Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT01125046
Phase
PHASE2
Status
Completed

Conditions

  • Acoustic Schwannoma
  • Adult Anaplastic Meningioma
  • Adult Ependymoma
  • Adult Grade I Meningioma
  • Adult Grade II Meningioma
  • Adult Meningeal Hemangiopericytoma
  • Adult Papillary Meningioma
  • Neurofibromatosis Type 1
  • Neurofibromatosis Type 2
  • Recurrent Adult Brain Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with recurrent or progression meningiomas.

Key Dates

First listed
May 18, 2010
Start date
Jun 17, 2010
Status verified
Oct 2020
Primary completion
Mar 10, 2014
Completion
Dec 31, 2018

Study Design

Enrollment
50 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm I
    Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months. Patients may then receive bevacizumab IV every 3 weeks for up to 12 months. Treatment continues in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Progression Free Survival (PFS) of Patients With Recurrent or Progressive Meningiomas Treated With Bevacizumab at 6 Months [ Time Frame: From the start of treatment and up until 6 months of treatment or follow up ]

Locations (5)

FacilityCityStateZIPSite coordinators
Northwestern UniversityChicagoIllinois60611-
Dana-Farber Cancer InstituteBostonMassachusetts02215-
Columbia University Medical CenterNew YorkNew York10032-
University of VirginiaCharlottesvilleVirginia22903-
University of WashingtonSeattleWashington98109-1023-

Find similar trials in Chicago, IL

By research site
Northwestern University· Chicago, ILDana-Farber Cancer Institute· Boston, MAColumbia University Medical Center· New York, NYUniversity of Virginia· Charlottesville, VAUniversity of Washington· Seattle, WA

Related Studies